<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585442</url>
  </required_header>
  <id_info>
    <org_study_id>22714</org_study_id>
    <secondary_id>10151812</secondary_id>
    <nct_id>NCT00585442</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D on Renin Expression in Hypertensive Patients</brief_title>
  <official_title>Effects of Calcitriol (1α, 25-[OH]2 Vitamin D3) on Renin Expression in Hypertensive Patients Without Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cardiovascular effects of vitamin D therapy (in humans) have been documented only in&#xD;
      patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of&#xD;
      inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin&#xD;
      D therapy extend beyond these patients to the general hypertensive population. We propose to&#xD;
      directly measure the effect of vitamin D therapy on plasma renin activity (PRA), plasma renin&#xD;
      concentration (PRC), renin transcription (in mononuclear leukocytes), and blood pressure in&#xD;
      hypertensive (but otherwise healthy) patients in a randomized, controlled, experimental&#xD;
      trial. This will be the first study to assess vitamin D receptor (VDR) biological (PRA, PRC,&#xD;
      renin mRNA, and polymorphisms) and hypertensive activity in patients without vitamin D&#xD;
      deficiency. We hypothesize that vitamin D inhibition of renin transcription will produce&#xD;
      significant reductions in PRA, PRC, renin transcription, inflammatory cytokines, SBP, and&#xD;
      DBP, with potential variation by VDR genotype. Such a result may prove to be significant in&#xD;
      the treatment of hypertension, as even modest blood pressure reductions (5 mmHg) are&#xD;
      associated with a 14% reduction in mortality due to stroke, a 9% reduction in mortality due&#xD;
      to CHD, and a 7% overall reduction in all-cause mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of quality data&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare plasma renin activity (PRA) and plasma renin concentration (PRC) in hypertensive patients (JNC VII stage I) following 14 days treatment with calcitriol (1α, 25-[OH]2 vitamin D3) or matched placebo.</measure>
    <time_frame>13 MONTHS (MAY 2007-JUNE 2008)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare mononuclear leukocyte renin transcription (mRNA) between calcitriol and matched placebo.</measure>
    <time_frame>13 MONTHS (MAY 2007-JUNE 2008)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcitriol</intervention_name>
    <description>1.0 mcg daily</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
    <other_name>1α, 25-[OH]2 Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients age &gt; 55 years.&#xD;
&#xD;
          2. Female patients must be postmenopausal, as determined by surgical hysterectomy or 12&#xD;
             month history since last active menstruation&#xD;
&#xD;
          3. Stage I hypertension (JNC VII Criteria): mean systolic blood pressure (mSBP) 140-159&#xD;
             mmHg and mean diastolic blood pressure 90 - 99 mmHg (mDBP)2&#xD;
&#xD;
          4. Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum vitamin D &lt;55 pmol/L&#xD;
&#xD;
          2. Serum calcium &gt;10.5 mg/dL&#xD;
&#xD;
          3. Serum phosphate (inorganic) &gt;5.5 mg/dL&#xD;
&#xD;
          4. Serum parathyroid hormone (PTH) &gt;1.3 pmol/L&#xD;
&#xD;
          5. Vitamin D supplements, calcium supplements, estrogen replacement therapy,&#xD;
             corticosteroids (inhaled/oral), or hydroxymethyl glutarate CoA reductase inhibitors&#xD;
             (statins) within 30 days prior to randomization&#xD;
&#xD;
          6. Stage II hypertension (JNC VII criteria): mSSBP &gt;160 mmHg or mSDBP &gt;100 mmHg&#xD;
&#xD;
          7. Use of alpha2-agonists, beta-blockers, or more than 2 anti-hypertensive medications at&#xD;
             screening&#xD;
&#xD;
          8. Estimated creatinine clearance &lt;30 mL/min by Crockroft-Gault Formula&#xD;
&#xD;
          9. History of heart failure (HF), acute myocardial infarction (AMI), acute coronary&#xD;
             syndrome (ACS), transient ischemic attack (TIA), cerebrovascular accident (CVA),&#xD;
             peripheral vascular disease (PVD), or known clotting disorder&#xD;
&#xD;
         10. Insulin dependent diabetes mellitus (patients stabilized on oral regimens may be&#xD;
             enrolled)&#xD;
&#xD;
         11. History of hypersensitivity reaction to 1α, 25-(OH)2 vitamin D3 (calcitriol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Munger, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>mark munger</investigator_full_name>
    <investigator_title>Professor, Pharmacotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

